Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations. In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements.
Indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
University of Texas Medical Branch, Galveston, Texas, United States
University of South Alabama Medical Center, Mobile, Alabama, United States
Loyola University Medical Center, Maywood, Illinois, United States
John's Hopkins Burn Center, Baltimore, Maryland, United States
Maricopa Integrated Health System, Phoenix, Arizona, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.